Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403146 | 0.91 | CYP2C19 (0.43) | ALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL6410244 | 0.86 | MAPK1 (0.44) | MAPK1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL2400767 | 0.81 | TSHR (0.44) | ALDH1A1POLBKMT2ARAB9A | |
| SCHEMBL6409697 | 0.79 | TSHR (0.48) | ALDH1A1LMNAOPRD1KMT2ARAB9A | |
| SCHEMBL2400415 | 0.78 | MEN1 (0.46) | ALDH1A1SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL2401367 | 0.78 | TSHR (0.46) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2402458 | 0.77 | PKM (0.53) | ALDH1A1SMN1; SMN2POLBKMT2A | |
| SCHEMBL2400977 | 0.77 | ALDH1A1 (0.48) | MAPK1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6412990 | 0.76 | CYP2C19 (0.41) | ALDH1A1SMN1; SMN2LMNAKMT2ARAB9A | |
| SCHEMBL2402499 | 0.75 | ALDH1A1 (0.55) | MAPK1ALDH1A1SMN1; SMN2POLBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | claimed |
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | MAPK1 4098/4885ALDH1A1 156/4885SMN1; SMN2 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.